Flexible formatting of AdAlta’s i-body technology

The customisable nature of the i-body, AdAlta’s next generation antibody, has recently been demonstrated in an article published by the well-respected and peer-reviewed journal mAbs, which can be downloaded here.

AdAlta holds a proprietary library of 20 billion i-body compounds that possess a long loop which enables access to difficult drug targets. The published paper demonstrates that the half-life of the i-body, or the time in which the i-body stays in the body, can be customised using multiple technologies (shown below). The ability to modify the half-life without affecting the binding properties of the long loop shows the flexibility of the i-body platform and increases the utility of the platform for treating a wide variety of diseases.

The customised formats of the i-body explored in the mAbs paper.

You can learn more about the i-body library and the process used to identify drug candidates from the library in an interview with AdAlta Chief Scientific Officer Dr Mick Foley. Mick has been with AdAlta since the beginning almost 12 years ago and in the video shares his greatest highlight over this time.

More information about AdAlta’s i-body technology can be found here.

If you would like to keep up to date with news on Adalta’s i-body platform and lead program, AD-214 for the treatment of Idiopathic Pulmonary Fibrosis, sign up to our subscriber list here.


A flurry of deals demonstrates the significant pharma interest in IPF

There has been considerable early-stage deal activity in the Idiopathic Pulmonary Fibrosis (IPF) space over the past few days, demonstrating the significant pharma interest in the area and boding well for AdAlta, which is soon to commence its Phase 1 human trials for its lead drug to treat the lethal lung disease Idiopathic Pulmonary Fibrosis (IPF).

On July 18 global pharma group, Boehringer Ingelheim announced it had licensed a Phase 1 IPF drug from Korean biotech firm, Bridge Biotherapeutics, for a near-term payment of EU45 million and up to EU1.1 billion in milestone payments. The deal follows Bridge Biotherapeutics announcement of positive interim pharmacokinetic and safety results from the first part of its Phase 1 study in May 2019.

Meanwhile, shares in Belgo-Dutch pharmaceutical research company, Galapagos (AMS: GLPG) reached an all-time high this week after it announced on July 14 that American biotech giant, Gilead (NASDAQ: GILD) will invest US$5.1 billion to raise its stake in the company to 22 per cent and partner with Galapagos develop and commercialise its treatments for a ten-year period, including its late-stage drugs for IPF.

Gilead is providing a US$3.95 billion upfront payment and a US$1.1 billion equity investment. The company will receive an exclusive license and options rights to develop and commercialise all of Galapagos’ current and future programs in all countries outside of Europe. This includes rights to Galapagos’ late-stage candidates, GLPG1690 and GLPG1205 which are currently in a Phase 3 and Phase 2 clinical studies for the treatment of IPF, respectively.

On July 1, biopharmaceutical company, Morphic Holding (NASDAQ: MORF) announced the closing of its initial public offering (IPO) following a capital raising of US$103.5 million. Morphic is focused on discovering and developing integrin therapeutics for the treatment of IPF. The successful IPO follows Morphic and pharma giant, Abbvie (NYSE: ABBV) completing a research and development collaboration designed to advance a number of Morphic’s therapeutics for fibrosis-related indications in October 2018. Morphic received an upfront payment of US$100 million for exclusive license options on product candidates directed at multiple targets.

This strong momentum is very promising for AdAlta as the company heads to Phase 1 human trials for its lead IPF drug candidate, AD-214 in January. IPF sadly remains a debilitating and fatal condition for which there is no cure – current treatments only slow the progression of the disease.

Also promising is a number of transactions with G-protein coupled receptor (GPCR) platforms over the past week.

GPCRs are a type of drug target, and AdAlta’s AD-214 binds to the GPCR, CXCR4. The company’s i-body, with its long loop also has greater access and high specificity for these types of drug targets and provides an opportunity to selectively modulate and drug these previously undruggable targets.

Researchers estimate that between one-third and one-half of all marketed drugs act by binding to GPCRs with 25% of the top 200 selling pharmaceuticals targeting GPCRs, and that has made them a big target for drug developers.

On July 16, Sosei Heptares inked a new deal with Roche’s (SWX: ROG) biologics unit, Genentech for a total of US$1 billion. Under the deal, the pair will seek to work on new meds that modulate GPCR targets “across a range of diseases.”

As well as its upcoming Phase 1 trial, AdAlta is also in advanced business development negotiations with potential partners for its i-body platform and is looking to complete 1-2 partnering transactions within the next six months.

These deals and an interest in the space AdAlta is working in, with AD-214 for the treatment of IPF and more broadly its i-body technology for partnering, demonstrate the significant pharma interest and potential opportunities for AdAlta. 

AusBiotech Case Study: Scarred for life

Australian biotechnology industry association AusBiotech has released a series of case studies that represent successful partnerships and investments in the Australian life sciences. AdAlta’s lead program, AD-214, has been featured in the case study released June 2019 called Scarred for Life.

The case study introduces fibrosis, specifically Idiopathic Pulmonary Fibrosis, the indication AD-214 is looking to target, and profiles AdAlta and Pharmaxis who are both companies “working towards re-designing the landscape of fibrosis treatment”.

The full case study can be viewed below and downloaded here. Additional information about AdAlta’s lead candidate, AD-214, being developed to treat Idiopathic Pulmonary Fibrosis can be viewed here.

Ausbiotech Fibrosis case study June 2019


Shareholder Update June 2019

AdAlta has had an exciting start to 2019 and we are pleased to share with you its first Shareholder Update for 2019. The update, which can be viewed below and downloaded here, includes an update on the progress of AD-214 to the clinic, further details on the collaboration with Excellerate Bioscience and links to all AdAlta mentions in the media as well as upcoming investor events.

Adalta Corporate Newsletter June 2019 4pp FINAL

CEO Sam Cobb updates the Morgans Network

AdAlta CEO Sam Cobb sat down with Scott Power to provide an update to the Morgans network regarding the recent funding round and what it means for AdAlta.

You can listen to the audio recording below and the ASX announcement can be viewed here.

CEO Sam Cobb in discussion with Proactive Investors

AdAlta CEO Sam Cobb spoke with Proactive Investors and provided insight into the recent successful completion of a $5 million Placement and covered how the funds will be used to progress both AdAlta’s lead candidate and i-body pipeline.

The interview can be viewed below and the ASX announcement regarding the placement can be viewed here.

Sam also discussed the Entitlement Offer that is currently open to all eligible shareholders. Information regarding the Entitlement Offer can be found on the Prospectus page here.

“The Rollercoaster Ride of a Biotech CEO” Sam Cobb profiled in US Life Science Leader

CEO Sam Cobb has recently been profiled by US business journal Life Science Leader, taking readers through her 12 year journey as the founding CEO of a biotech company. It has been “a roller-coaster ride of personal growth”  including navigating capital raising, rebounding from deals that fell apart and managing setbacks in moving the lead candidate through to clinical trials.

You can view the article on the Life Science Leader website here.

If you would like to learn more about AdAlta’s lead candidate, AD-214, for Idiopathic Pulmonary Fibrosis click here.

CEO Sam Cobb shares her leadership experiences with Stockhead

AdAlta CEO Sam Cobb was recently profiled by Stockhead in the first of a “Women in Leadership” series as a follow-on from their February article that “reported that less than 30 small caps have equal representation of women on their boards – and there’s more than 1700 companies with a market cap of $400m or less“.

Sam shared her views on women putting themselves for leadership roles, the imbalance between more women in science but a lack of growth at the top of the corporate ladder as well as her experience dealing with investors, where there is lack of women on the other side of the table also.

The article titled “Why comments like ‘I’m remembered because I’m a female’ prove we (still) don’t have enough women at the top” can be viewed on the Stockhead website here.

The Pathway to the Clinic: Special Investor/Analyst Briefing 2019

[Best_Wordpress_Gallery id=”13″ gal_title=”Investor Briefing 2019″]

“I think we now, within the Pharmaceuticals industry and in biotechnology, understand that there is three main things we have to keep in mind: the right target, the right drug and the right patient”

These words from AdAlta Scientific Advisory Board member Dr John Westwick summed up AdAlta’s third annual Special Investor/Analyst Briefing held on January 31, 2019. Check out the short highlights video to see why these pharmaceutical veterans believe that AdAlta’s lead program, AD-214, has the exciting potential to meet all of these three key criteria.

With AD-214 moving through final preclinical stages before entering clinical trials in 2020, the day focused on the pathway to drug development and brought together a range of medical, scientific and pharmaceutical experts.

Investors and analysts also heard about AdAlta’s progress as well as the need for new IPF treatments and the benefits of investing in Australian biotechnology companies. It included a panel session on ‘What a good drug looks like‘, an often under-appreciated topic when developing a new therapeutic.

A highlight of the day was hearing from Idiopathic Pulmonary Fibrosis patient Bill Van Nierop. Bill discussed the impact of IPF and his tremendous efforts to raise awareness of the disease – one that kills more people in Australia than breast cancer but “gets no mention, anywhere”.

Individual Speaker Presentations

‘An IPF patient’s perspective’

IPF Clinician Dr Glen Westall ‘Current state of play in IPF’

Clinician Dr Steve Felstead – ‘The IPF Landscape’

AdAlta Chief Operating Officer – Dr Dallas Hartman ‘Manufacturing of AD-214’

AdAlta non-executive Director – Dr Robert Peach ‘Therapeutic Fc Fusion Proteins’

Panel Discussion – Dr Brian Richardson, Dr John Westwick, Dr Steve Felstead and Dr Robert Peach ‘What does a good drug look like?’

Chairman and Founder of Private Portfolio Managers – Hugh MacNally ‘Investing in Biotech, what does it take?’

AdAlta CEO – Sam Cobb – ‘Update on lead program AD-214’